FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2053252034> ?p ?o ?g. }

• W2053252034 endingPage "1575" @default.
• W2053252034 startingPage "1567" @default.
• W2053252034 abstract "Overexpression of epidermal growth factor receptor (EGFR) and angiogenic factors is associated with the progression of androgen-independent prostate cancer (AIPC). We examined the effects of vandetanib, an inhibitor of vascular endothelial growth factor (VEGFR), EGFR, and rearranged during transfection (RET) tyrosine-kinase activities, alone or combined with docetaxel, on PC3 docetaxel-sensitive (PC3wt) or docetaxel-resistant (PC3R) AIPC cell growth in vivo and in vitro. Mice bearing PC3wt or PC3R tumors were treated for 3 weeks with vandetanib (25 or 50 mg/kg/d p.o., 5 d/wk), docetaxel (10 or 30 mg/kg i.p., 1 d/wk), or their combination (low or high doses). Xenograft tumors were analyzed for expression of Ki-67, EGFR, VEGFR2, and production of VEGFA. On PC3wt, vandetanib at both doses stimulated tumor growth, whereas docetaxel at both doses exerted strong growth-inhibiting effects. The low-dose vandetanib-docetaxel combination resulted in tumor growth similar to that of control, whereas the high-dose combination induced a significant antiproliferative effect. In contrast, on PC3R, the low-dose of vandetanib had no effect on tumor growth, whereas the high-dose of vandetanib significantly inhibited tumor growth. Docetaxel at both doses exerted moderate and transient antitumor effects. The combination of high-dose vandetanib with high-dose docetaxel resulted in antiproliferative effects, which were lower than expected from the sum of individual drug effects. Importantly, tumor analyses revealed overexpression of the EGFR/VEGFR pathways in PC3R relative to PC3wt. Present results suggest that vandetanib should not be associated with docetaxel in treatment-naive or docetaxel-resistant prostate cancer (CaP). The use of high-dose vandetanib alone may warrant further investigation in patients with docetaxel-resistant AIPC overexpressing VEGFR/EGFR pathways." @default.
• W2053252034 created "2016-06-24" @default.
• W2053252034 creator A5006266119 @default.
• W2053252034 creator A5011010900 @default.
• W2053252034 creator A5015046932 @default.
• W2053252034 creator A5021854687 @default.
• W2053252034 creator A5043290265 @default.
• W2053252034 creator A5047469475 @default.
• W2053252034 creator A5047669876 @default.
• W2053252034 creator A5052110718 @default.
• W2053252034 creator A5055514871 @default.
• W2053252034 creator A5068216735 @default.
• W2053252034 creator A5076271611 @default.
• W2053252034 creator A5079265441 @default.
• W2053252034 creator A5081001489 @default.
• W2053252034 creator A5090050048 @default.
• W2053252034 creator A5090083053 @default.
• W2053252034 date "2013-11-01" @default.
• W2053252034 modified "2023-10-18" @default.
• W2053252034 title "Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines" @default.
• W2053252034 cites W1528893072 @default.
• W2053252034 cites W153934429 @default.
• W2053252034 cites W1964950171 @default.
• W2053252034 cites W1967600348 @default.
• W2053252034 cites W1977202771 @default.
• W2053252034 cites W1980637728 @default.
• W2053252034 cites W2006202974 @default.
• W2053252034 cites W2011011592 @default.
• W2053252034 cites W2021058219 @default.
• W2053252034 cites W2023375628 @default.
• W2053252034 cites W2033261019 @default.
• W2053252034 cites W2044703558 @default.
• W2053252034 cites W2058034201 @default.
• W2053252034 cites W2080709087 @default.
• W2053252034 cites W2085802928 @default.
• W2053252034 cites W2101995865 @default.
• W2053252034 cites W2102727906 @default.
• W2053252034 cites W2109833554 @default.
• W2053252034 cites W2113971256 @default.
• W2053252034 cites W2118559000 @default.
• W2053252034 cites W2120292596 @default.
• W2053252034 cites W2134999841 @default.
• W2053252034 cites W2140088548 @default.
• W2053252034 cites W2143246086 @default.
• W2053252034 cites W2148140793 @default.
• W2053252034 cites W2152099731 @default.
• W2053252034 cites W2166949776 @default.
• W2053252034 cites W2611334505 @default.
• W2053252034 doi "https://doi.org/10.1016/j.urolonc.2012.03.003" @default.
• W2053252034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22608542" @default.
• W2053252034 hasPublicationYear "2013" @default.
• W2053252034 type Work @default.
• W2053252034 sameAs 2053252034 @default.
• W2053252034 citedByCount "2" @default.
• W2053252034 countsByYear W20532520342020 @default.
• W2053252034 countsByYear W20532520342021 @default.
• W2053252034 crossrefType "journal-article" @default.
• W2053252034 hasAuthorship W2053252034A5006266119 @default.
• W2053252034 hasAuthorship W2053252034A5011010900 @default.
• W2053252034 hasAuthorship W2053252034A5015046932 @default.
• W2053252034 hasAuthorship W2053252034A5021854687 @default.
• W2053252034 hasAuthorship W2053252034A5043290265 @default.
• W2053252034 hasAuthorship W2053252034A5047469475 @default.
• W2053252034 hasAuthorship W2053252034A5047669876 @default.
• W2053252034 hasAuthorship W2053252034A5052110718 @default.
• W2053252034 hasAuthorship W2053252034A5055514871 @default.
• W2053252034 hasAuthorship W2053252034A5068216735 @default.
• W2053252034 hasAuthorship W2053252034A5076271611 @default.
• W2053252034 hasAuthorship W2053252034A5079265441 @default.
• W2053252034 hasAuthorship W2053252034A5081001489 @default.
• W2053252034 hasAuthorship W2053252034A5090050048 @default.
• W2053252034 hasAuthorship W2053252034A5090083053 @default.
• W2053252034 hasConcept C121608353 @default.
• W2053252034 hasConcept C126322002 @default.
• W2053252034 hasConcept C143998085 @default.
• W2053252034 hasConcept C167734588 @default.
• W2053252034 hasConcept C170493617 @default.
• W2053252034 hasConcept C2777025900 @default.
• W2053252034 hasConcept C2778820342 @default.
• W2053252034 hasConcept C2779438470 @default.
• W2053252034 hasConcept C2780192828 @default.
• W2053252034 hasConcept C2780333294 @default.
• W2053252034 hasConcept C2781190966 @default.
• W2053252034 hasConcept C42362537 @default.
• W2053252034 hasConcept C502942594 @default.
• W2053252034 hasConcept C71924100 @default.
• W2053252034 hasConcept C98274493 @default.
• W2053252034 hasConceptScore W2053252034C121608353 @default.
• W2053252034 hasConceptScore W2053252034C126322002 @default.
• W2053252034 hasConceptScore W2053252034C143998085 @default.
• W2053252034 hasConceptScore W2053252034C167734588 @default.
• W2053252034 hasConceptScore W2053252034C170493617 @default.
• W2053252034 hasConceptScore W2053252034C2777025900 @default.
• W2053252034 hasConceptScore W2053252034C2778820342 @default.
• W2053252034 hasConceptScore W2053252034C2779438470 @default.
• W2053252034 hasConceptScore W2053252034C2780192828 @default.
• W2053252034 hasConceptScore W2053252034C2780333294 @default.
• W2053252034 hasConceptScore W2053252034C2781190966 @default.

• next